Tokyo, Japan, Dec 26, 2005 - (JCN Newswire) - Eisai Co., Ltd, Tokyo, Japan (TSE: 4523) and Abbott Japan Co., Ltd. today submitted a new drug application (NDA) to the Minister of Health Labour and Welfare (MHLW) for the manufacturing and marketing for the rheumatoid arthritis drug adalimumab (D2E7), which is co-developed by the two companies in Japan. Adalimumab (D2E7) resembles antibodies normally found in the human body. It works by neutralizing TNF-, a protein that plays a central role in the inflammatory responses of autoimmune disease such as rheumatoid arthritis.
